Jennifer K. Litton
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Breast Cancer Treatment Studies, BRCA gene mutations in cancer, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies
Most-Cited Works
- → Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation(2018)2,082 cited
- → PD-L1 Expression in Triple-Negative Breast Cancer(2014)1,378 cited
- → Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology(2021)1,099 cited
- → PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression(2017)954 cited
- → Breast Cancer Before Age 40 Years(2009)775 cited
- → Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1(2018)740 cited
- → NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017(2016)657 cited
- → Genetic/Familial High-Risk Assessment: Breast and Ovarian(2010)650 cited
- → Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer(2011)600 cited
- → Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian(2014)505 cited